Allogeneic hematopoietic stem cell transplantation: Does it have a place in treating hodgkin lymphoma?

Current Hematologic Malignancy Reports

Volumn 5, Issue 4, 2010, Pages 229-238

  Salit, Rachel B ^b   Bishop, Michael R ^a   Pavletic, Steven Z ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

Graft versus lymphoma effect; Hodgkin lymphoma; Reduced intensity conditioning; Stem cell transplantation; Treatment

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS LYMPHOMA EFFECT; HODGKIN DISEASE; MYELOABLATIVE CONDITIONING; PROGNOSIS; REDUCED INTENSITY CONDITIONING; REVIEW; WHOLE BODY RADIATION;

CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; PROGNOSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77958494188     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0065-7     Document Type: Review

References (43)

1. RM Meyer MK Gospodarowicz JM Connors, et al. 2005 Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group J Clin Oncol 23 4634 4642 1:CAS:528:DC%2BD2MXotFarsrY%3D 10.1200/JCO.2005.09.085 15837968 (Pubitemid 46237440)
2. G Bonadonna V Bonfante S Viviani, et al. 2004 ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results J Clin Oncol 22 2835 2841 10.1200/JCO.2004.12.170 15199092 (Pubitemid 41079901)
3. DB Duggan GR Petroni JL Johnson, et al. 2003 Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial J Clin Oncol 21 607 614 1:CAS:528:DC%2BD2cXpsVGrtbg%3D 10.1200/JCO.2003.12.086 12586796 (Pubitemid 46621893)
4. PG Gobbi A Levis T Chisesi, et al. 2005 ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi J Clin Oncol 23 9198 9207 1:CAS:528:DC%2BD28Xnt1ynsw%3D%3D 10.1200/JCO.2005.02.907 16172458
5. DC Linch D Winfield AH Goldstone, et al. 1993 Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial Lancet 341 1051 1054 1:STN:280:DyaK3s3isFOisg%3D%3D 10.1016/0140-6736(93)92411-L 8096958 (Pubitemid 23114397)
6. N Schmitz B Pfistner M Sextro, et al. 2002 Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial Lancet 359 2065 2071 1:CAS:528:DC%2BD38XkslGhs7w%3D 10.1016/S0140-6736(02)08938-9 12086759 (Pubitemid 34680969)
7. JM Vose PJ Bierman JR Anderson, et al. 1992 Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up Blood 80 2142 2148 1:STN:280: DyaK3s%2FgsVOrsA%3D%3D 1356515
8. M Varterasian V Ratanatharathorn JP Uberti, et al. 1995 Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation Leuk Lymphoma 20 59 65 1:STN:280:DyaK28zltF2luw%3D%3D 10.3109/10428199509054754 8750624
9. L Castagna M Magagnoli M Balzarotti, et al. 2007 Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study Am J Hematol 82 122 127 1:CAS:528:DC%2BD2sXhvFCmsr0%3D 10.1002/ajh.20790 17019686 (Pubitemid 46155274)
10. FR Appelbaum KM Sullivan ED Thomas, et al. 1985 Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease J Clin Oncol 3 1490 1494 1:STN:280:DyaL28%2Fjs1emtQ%3D%3D 2414410
11. GL Phillips SN Wolff RH Herzig, et al. 1989 Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation Blood 73 2086 2092 1:STN:280:DyaL1M3nsVeruw%3D%3D 2659100
12. RJ Jones S Piantadosi RB Mann, et al. 1990 High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease J Clin Oncol 8 527 537 1:STN:280:DyaK3c7nt1ShtA%3D%3D 2307990
13. JE Anderson MR Litzow FR Appelbaum, et al. 1993 Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience J Clin Oncol 11 2342 2350 1:STN:280:DyaK2c%2FmsFyltw%3D%3D 8246023
14. N Milpied AK Fielding RM Pearce, et al. 1996 Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation J Clin Oncol 14 1291 1296 1:STN:280:DyaK283ktlSqtg%3D%3D 8648386
15. AJ Peniket MC Ruiz de Elvira G Taghipour, et al. 2003 An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation Bone Marrow Transplant 31 667 678 1:STN:280:DC%2BD3s7ntlekuw%3D%3D 10.1038/sj.bmt.1703891 12692607 (Pubitemid 36553477)
16. JL Gajewski GL Phillips KA Sobocinski, et al. 1996 Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease J Clin Oncol 14 572 578 1:STN:280:DyaK283itlCitQ%3D%3D 8636773
17. G Akpek RF Ambinder S Piantadosi, et al. 2001 Long-term results of blood and marrow transplantation for Hodgkin's lymphoma J Clin Oncol 19 4314 4321 1:STN:280:DC%2BD3MnosFWnsg%3D%3D 11731514
18. G Bonadonna S Viviani V Bonfante, et al. 2005 Survival in Hodgkin's disease patients-report of 25 years of experience at the Milan Cancer Institute Eur J Cancer 41 998 1006 10.1016/j.ejca.2005.01.006 15862748 (Pubitemid 40602851)
19. B Sirohi D Cunningham R Powles, et al. 2008 Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma Ann Oncol 19 1312 1319 1:STN:280:DC%2BD1cvgvVyitg%3D%3D 10.1093/annonc/mdn052 18356139 (Pubitemid 351911964)
20. A Sureda S Robinson C Canals, et al. 2008 Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol 26 455 462 1:CAS:528:DC%2BD1cXitVGnurk%3D 10.1200/JCO.2007.13.2415 18086796 This retrospective analysis was the first to compare reduced-intensity conditioning with myeloablative stem cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. The results demonstrated nearly twice the relapse incidence in the reduced-intensity conditioning group. However, the 5-year overall survival was significantly higher in the reduced-intensity conditioning group, likely because of the lower 1-year nonrelapse mortality (Pubitemid 351171699)
21. SP Robinson A Sureda C Canals, et al. 2009 Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome Haematologica 94 230 238 10.3324/haematol.13441 19066328 This retrospective analysis attempted to predict factors that determine post-transplant outcome following reduced-intensity conditioning transplantation for Hodgkin lymphoma. In multivariate analysis, patients who received fewer lines of chemotherapy and those in complete remission had significantly lower rates of disease progression than patients with refractory disease at the time of reduced-intensity conditioning. Patients with a good performance status, in a complete remission, or with chemosensitive disease had significantly better progression-free survival and overall survival
22. MP Devetten PN Hari J Carreras, et al. 2009 Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma Biol Blood Marrow Transplant 15 109 117 10.1016/j.bbmt.2008.11.011 19135949
23. KS Peggs A Hunter R Chopra, et al. 2005 Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation Lancet 365 1934 1941 10.1016/S0140-6736(05)66659-7 15936420 (Pubitemid 40797503)
24. I Alvarez A Sureda MD Caballero, et al. 2006 Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol Biol Blood Marrow Transplant 12 172 183 10.1016/j.bbmt.2005.09.009 16443515 (Pubitemid 43138012)
25. P Anderlini R Saliba S Acholonu, et al. 2005 Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen Bone Marrow Transplant 35 943 951 1:CAS:528:DC%2BD2MXjvVans7o%3D 10.1038/sj.bmt.1704942 15806128 (Pubitemid 40711829)
26. P Anderlini R Saliba S Acholonu, et al. 2008 Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience Haematologica 93 257 264 1:CAS:528: DC%2BD1cXhsVSiu7zK 10.3324/haematol.11828 18223284 (Pubitemid 351397714)
27. M Todisco 2007 Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin Am J Ther 14 113 115 10.1097/01.mjt.0000209675.83958.9c 17303979 (Pubitemid 46278672)
28. NS Majhail DJ Weisdorf JE Wagner, et al. 2006 Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma Blood 107 3804 3807 1:CAS:528:DC%2BD28Xkt1Ghsrk%3D 10.1182/blood-2005-09-3827 16384924
29. LM Burroughs PV O'Donnell BM Sandmaier, et al. 2008 Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma Biol Blood Marrow Transplant 14 1279 1287 10.1016/j.bbmt.2008.08.014 18940683
30. L Castagna B Sarina E Todisco, et al. 2009 Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma Biol Blood Marrow Transplant 15 432 438 1:CAS:528:DC%2BD1MXkslKhtbk%3D 10.1016/j.bbmt.2008.12.506 19285630
31. KJ Thomson KS Peggs P Smith, et al. 2008 Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation Bone Marrow Transplant 41 765 770 1:STN:280:DC%2BD1czhtlegtA%3D%3D 10.1038/sj.bmt.1705977 18195684 (Pubitemid 351696339)
32. B Sarina L Castagna L Farina, et al. 2010 Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability Blood 115 3671 3677 1:CAS:528:DC%2BC3cXms1egurk%3D 10.1182/blood-2009-12-253856 20220116 A retrospective analysis was performed in 185 Hodgkin lymphoma patients who had HLA typing performed immediately after failed autologous stem cell transplantation to compare allogeneic stem cell transplantation versus conventional treatment in patients with relapsed or refractory Hodgkin lymphoma. In an intent-to-treat analysis, 4-year progression-free survival and overall survival were significantly better in the donor group (P∈<∈0.001)
33. KS Peggs A Sureda W Qian, et al. 2007 Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes Br J Haematol 139 70 80 1:CAS:528:DC%2BD2sXht1SmtLrK 10.1111/j.1365-2141.2007.06759.x 17854309 (Pubitemid 47389932)
34. Sureda A, Canals C, Arranz R, et al.: Allogeneic stem cell transplantation after reduced intensity conditioning (RIC-allo) in patients with relapsed or refractory Hodgkin's lymphoma (HL). Final analysis of the HDR-Allo protocol-a prospective clinical trial by the Grupo Espanol de Linfomas / Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 658.
35. A Josting U Rueffer J Franklin, et al. 2000 Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group Blood 96 1280 1286 1:CAS:528: DC%2BD3cXlvF2itL8%3D 10942369
36. KA David L Mauro AM Evens 2007 Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options Curr Treat Options Oncol 8 352 374 10.1007/s11864-007-0046-9 18214690
37. A Josting J Franklin M May, et al. 2002 New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group J Clin Oncol 20 221 230 10.1200/JCO.20.1.221 11773173 (Pubitemid 34032615)
38. E Jabbour C Hosing G Ayers, et al. 2007 Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma Cancer 109 2481 2489 10.1002/cncr.22714 17497648 (Pubitemid 46906468)
39. L Castagna S Bramanti M Balzarotti, et al. 2009 Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy Br J Haematol 145 369 372 1:CAS:528:DC%2BD1MXlslOhs78%3D 10.1111/j.1365-2141.2009.07645.x 19344403
40. B Klimm R Schnell V Diehl A Engert 2005 Current treatment and immunotherapy of Hodgkin's lymphoma Haematologica 90 1680 1692 1:CAS:528:DC%2BD28XltVeiuw%3D%3D 16330443
41. R Schnell M Dietlein JO Staak, et al. 2005 Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody J Clin Oncol 23 4669 4678 1:CAS:528:DC%2BD2MXotFarsrc%3D 10.1200/JCO.2005.09.098 16034043 (Pubitemid 46224069)
42. NL Bartlett A Younes MH Carabasi, et al. 2008 A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies Blood 111 1848 1854 1:CAS:528:DC%2BD1cXisVeisrg%3D 10.1182/blood-2007-07-099317 18079362 (Pubitemid 351451492)
43. A Forero-Torres JP Leonard A Younes, et al. 2009 A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma Br J Haematol 146 171 179 1:CAS:528:DC%2BD1MXps1OitL8%3D 10.1111/j.1365-2141.2009.07740.x 19466965